Provincial Drug Reimbursement Programs
Cancer Care Ontario administers 3 drug funding programs on behalf of the Ministry of Health and Long-Term Care. Through these programs we reimburse hospitals and regional cancer centres for injectable cancer drugs used according to established funding criteria. All of our programs are managed by the Provincial Drug Reimbursement Programs Unit.
If you are a patient looking for funding information, we encourage you to speak to your healthcare team for more information.
New Drug Funding Program
The New Drug Funding Program is a publicly funded drug program under the Ontario Public Drug Programs. The program pays for many newer, and often very expensive, injectable cancer drugs administered in hospitals and cancer centres.
About the Program
Find out who is eligible, what types of drugs the program funds and how healthcare providers can submit enrolment forms and patient information.
Funding for Systemic Treatment Clinical Trials
Find the policy on the reimbursement of cancer drugs for patients receiving treatment through clinical trials, and information about the related funding streams.
Drug Funding FAQs
Get the answers to many commonly asked questions about cancer drug costs and funding programs in Ontario.
Biosimilars Initiatives
Learn about our work to support the implementation of biosimilars, including the pan-Canadian Oncology Biosimilars Initiative, and a Biosimilar Implementation Evaluation Framework.
Evidence Building Program
The Evidence Building Program covers the cost of cancer drugs in situations where there is developing, but incomplete evidence of benefits. The program helps to strengthen the process for making drug funding decisions in Ontario.
About Evidence Building Program
Find out who is eligible, what types of drugs the program funds and how healthcare providers can submit enrolment and supplemental forms for patients.
Evidence Building Program Policy
Learn about the objectives of the program and the inclusion criteria used to determine which drugs will be considered under the program.
Summary and Response to Stakeholder Consultation
Consultations were held with clinicians, researchers, pharmacists, members of the public and others during the development of the Evidence Building Program.
Case-by-Case Review Program
The Case-by-Case Review Program considers funding requests for oral and injectable cancer drugs for cancer patients who have rare clinical circumstances that are immediately life threatening, and who require treatment with an unfunded drug because there is no other satisfactory and funded treatment.
About Case-by-Case Review Program
Find out who is eligible, what types of drugs the program funds, how oncologists can submit a patient application and pharmacists can submit a claim.
Case-by-Case Review Program Policy
Learn about the program’s scope and the funding criteria used to determine which drugs will be considered under the program.